Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ACI-24 formulations in mild Alzheimer's disease
2018-000445-39Phase 2Completed
- Sponsor
- AC Immune SA
- Start
- May 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing ACI-24 formulation arm with Placebo arm (2 arms). Primary endpoint: Safety and tolerability. Started May 2018; status: completed.
02
Drugs
ACI-24
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2018-000445-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000445-39.